“`html
AbbVie Inc. (ABBV) reported its third-quarter earnings for 2025 on October 27, 2025, posting an adjusted EPS of $1.86, surpassing the Zacks Consensus Estimate of $1.77 and the company’s earlier guidance of $1.74-$1.78. However, this marks a 38% decline year over year. The company’s revenue for the quarter was $15.78 billion, exceeding the consensus estimate of $15.59 billion and the company’s forecast of $15.5 billion, reflecting a 9.1% increase year over year.
Key drivers for the revenue growth included significant sales from immunology drugs like Rinvoq, which reached $2.18 billion (up 34.1%), and Skyrizi, with revenues of $4.71 billion (up 46.0%). In contrast, sales of its flagship product Humira fell 55.7% to $993 million, attributed to the loss of exclusivity. The neuroscience portfolio also performed well, generating $2.84 billion (up 19.6%), while oncology sales decreased slightly to $1.68 billion, driven by declining Imbruvica sales.
AbbVie has raised its 2025 adjusted EPS guidance to a range of $10.61-$10.65, an increase from the previous estimate of $10.38-$10.58. The company’s stock has gained 28% year to date, compared to the industry average growth of 3%.
“`
